Sandbox gc

Revision as of 03:35, 24 October 2017 by GeraldChi (talk | contribs)
Jump to navigation Jump to search


Summary of clinical trial phases
Phase Primary goal Dose Patient monitor Typical number of participants
Preclinical Testing of drug in non-human subjects, to gather efficacy, toxicity and pharmacokinetic information unrestricted scientific researcher not applicable (in vitro and in vivo only)
Phase 0 Pharmacokinetics; particularly, oral bioavailability and half-life of the drug very small, subtherapeutic clinical researcher  10 people
Phase I Testing of drug on healthy volunteers for dose-ranging often subtherapeutic, but with ascending doses clinical researcher 20–100 normal healthy volunteers (or for cancer drugs, cancer patients)
Phase II Testing of drug on patients to assess efficacy and side effects therapeutic dose clinical researcher 100–300 patients with specific diseases
Phase III Testing of drug on patients to assess efficacy, effectiveness and safety therapeutic dose clinical researcher and personal physician 300–3,000 patients with specific diseases
Phase IV Postmarketing surveillance – watching drug use in public therapeutic dose personal physician anyone seeking treatment from their physician